Trade Chinook Therapeutics, Inc. - KDNY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.26 |
| Open | 40.28 |
| 1-Year Change | 107.42% |
| Day's Range | 40.24 - 40.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 10, 2023 | 40.34 | 0.09 | 0.22% | 40.25 | 40.45 | 40.24 |
| Aug 9, 2023 | 40.26 | 0.03 | 0.07% | 40.23 | 40.27 | 40.22 |
| Aug 8, 2023 | 40.27 | 0.04 | 0.10% | 40.23 | 40.32 | 40.23 |
| Aug 7, 2023 | 40.27 | 0.06 | 0.15% | 40.21 | 40.33 | 40.20 |
| Aug 4, 2023 | 40.23 | 0.02 | 0.05% | 40.21 | 40.24 | 40.20 |
| Aug 3, 2023 | 40.24 | 0.09 | 0.22% | 40.15 | 40.25 | 40.15 |
| Aug 2, 2023 | 40.14 | -0.10 | -0.25% | 40.24 | 40.27 | 40.07 |
| Aug 1, 2023 | 40.24 | -0.01 | -0.02% | 40.25 | 40.41 | 40.21 |
| Jul 31, 2023 | 39.12 | 0.13 | 0.33% | 38.99 | 39.22 | 38.90 |
| Jul 28, 2023 | 39.02 | 0.07 | 0.18% | 38.95 | 39.05 | 38.90 |
| Jul 27, 2023 | 38.89 | -0.15 | -0.38% | 39.04 | 39.10 | 38.84 |
| Jul 26, 2023 | 39.03 | -0.01 | -0.03% | 39.04 | 39.07 | 38.86 |
| Jul 25, 2023 | 39.03 | -0.07 | -0.18% | 39.10 | 39.18 | 39.01 |
| Jul 24, 2023 | 39.19 | 0.31 | 0.80% | 38.88 | 39.31 | 38.86 |
| Jul 21, 2023 | 38.84 | -0.20 | -0.51% | 39.04 | 39.20 | 38.81 |
| Jul 20, 2023 | 39.04 | -0.12 | -0.31% | 39.16 | 39.27 | 38.95 |
| Jul 19, 2023 | 39.15 | -0.16 | -0.41% | 39.31 | 39.39 | 39.13 |
| Jul 18, 2023 | 39.29 | -0.04 | -0.10% | 39.33 | 39.48 | 39.28 |
| Jul 17, 2023 | 39.33 | 0.17 | 0.43% | 39.16 | 39.35 | 39.12 |
| Jul 14, 2023 | 39.18 | 0.08 | 0.20% | 39.10 | 39.19 | 39.02 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chinook Therapeutics, Inc. Company profile
About Chinook Therapeutics Inc
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chinook Therapeutics Inc revenues increased from $827K to $51.6M. Net loss increased 26% to $102.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development-other increase from $24.8M to $66.1M (expense), Change in fair value of contingent consi increase from $1.5M to $27.3M (expense).
| Industry: | Bio Therapeutic Drugs |
400 Fairview Avenue North, Suite 900
SEATTLE
WASHINGTON 98109
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com